Peptide Therapy Explained: What Are Peptides and Why Does It Matter Where They Come From?

Peptides are one of the fastest-growing conversations in functional and integrative medicine right now. You have likely seen them mentioned on podcasts, by health influencers, or in articles about longevity and recovery. You may have also seen them sold directly online without a prescription. That combination, growing interest and easy accessibility, is exactly why it is worth slowing down and understanding what peptides actually are, how the more commonly discussed ones work, and why where they come from matters as much as what they are.

At Valley Vital Medicine in Fargo, ND, we believe that informed patients make better decisions. This post is intended to give you a clear, grounded overview of peptides, the current regulatory environment, and three of the peptides receiving the most attention in integrative medicine today.

What Is a Peptide?

A peptide is a short chain of amino acids. A long chain of amino acids is called a protein. If amino acids are individual Lego bricks, a peptide is a small structure built from a handful of those bricks, while a protein is a much larger, more complex structure built from hundreds or even thousands.

What makes peptides particularly interesting is not their structure but their function. Peptides act as signaling molecules. They are, in many ways, the body's internal messaging system. Think of the body as a large city full of construction crews, electricians, doctors, and dispatchers. Everyone already knows how to do their job, but nothing gets done efficiently unless people are communicating. Peptides carry those instructions. They tell cells what to do, when to do it, and how much of it is needed.

Your body already produces thousands of different peptides naturally. Researchers have identified over 7,000 naturally occurring peptides in humans. The pancreas produces peptides involved in blood sugar regulation. The stomach produces peptides involved in digestion. The thymus gland produces peptides that coordinate immune responses. The skin produces peptides involved in wound healing. This is important because therapeutic peptides are not introducing a foreign signal. They are working with the body's own language.

Why Is Everyone Talking About Peptides Now?

Peptides are not new. Insulin, which is itself a peptide, has been used in medicine for over 100 years. Growth hormone, oxytocin, and calcitonin are also peptides that have been part of medicine for decades.

What has changed is our understanding. For most of the twentieth century, medicine focused on blocking pathways rather than supporting them. If blood pressure was high, we blocked an enzyme. If cholesterol was elevated, we blocked the pathway that produces it. Peptide therapy asks a different question: what if instead of forcing the body to do something, we help it communicate better and do what it was already designed to do?

The explosion of GLP-1 medications such as semaglutide and tirzepatide has also brought peptides into mainstream awareness. Many people realized for the first time that GLP-1 medications are themselves peptides, and that naturally sparked curiosity about what other peptides might be able to do.

The Regulatory Landscape: What the FDA Actually Said

If you have followed the news around peptides recently, you may have seen headlines suggesting that several peptides were just approved or that major changes happened overnight. That is not accurate, and the distinction matters.

The FDA's Pharmacy Compounding Advisory Committee met recently to review several peptides and voted on whether they should be eligible for compounding by licensed pharmacies. Six of the seven reviewed peptides received favorable recommendations. That is genuinely encouraging news for patients and practitioners who use these therapies. However, the advisory committee makes recommendations, it does not make final decisions. The FDA reviews those recommendations, gathers public input, and determines the regulatory outcome. That process takes months. Nothing became FDA-approved. Nothing suddenly became widely available. It is one important step forward in a longer process.

Three Categories of Peptides: Understanding the Difference

One of the most common mistakes people make when researching peptides is assuming they all fall into the same category. They do not.

The first category is FDA-approved peptide medications. These include insulin, GLP-1 medications like semaglutide and tirzepatide, certain fertility medications, and growth hormone. These have gone through years of clinical trials, established dosing, known side effects, and defined indications.

The second category is compounded peptides. These are medications prepared by licensed compounding pharmacies under a physician's prescription. Compounding has a long history in medicine and exists to serve patients who need medications in specific doses, formulations, or without certain ingredients. This is where many therapeutic peptides currently sit, and this is the category the FDA advisory committee was reviewing.

The third category is gray market or online peptides purchased directly without a prescription or clinical oversight. This category carries the most risk and requires the most caution.

Why the Source Matters as Much as the Peptide

If you needed a heart medication, you would not purchase it from an anonymous website because it was less expensive. The same logic applies to peptides.

Licensed compounding pharmacies operate under strict standards. Ingredients come from qualified suppliers. Sterility procedures are monitored. Batches are tested. Certificates of analysis are maintained. Many pharmacies perform additional purity and concentration testing before dispensing.

Independent analyses of peptides purchased online have found products that contain less active ingredient than advertised, products with greater concentrations than labeled, and in some cases products with bacterial contamination. Because most therapeutic peptides are administered by injection, contamination is not a minor concern. It is a patient safety issue.

Dosing accuracy matters too. If a vial is supposed to contain 10 milligrams but actually contains a significantly different amount, you are not getting the expected response. Medicine requires predictable, consistent dosing. Gray market products cannot reliably provide that.

Clinical oversight matters as well. Determining the right peptide, the appropriate dose, the correct frequency, potential interactions with other medications, and whether lab monitoring is needed requires a provider who understands the full picture. Forums and social media are not a substitute for that.

Thymosin Alpha-1: The Immune System's Conductor

Thymosin Alpha-1 originates in the thymus gland, a small organ that sits just behind the breastbone. In infants and young children, the thymus is one of the most active immune organs in the body. It functions as a training academy for T cells, the immune cells responsible for recognizing and responding to threats. More than 95% of immature T cells never pass quality control and are removed before they enter circulation.

The problem is that the thymus does not remain active. Beginning around puberty, it starts to shrink in a process called thymic involution. By the late 30s and early 40s, research suggests the thymus has lost the majority of its functional tissue. By age 65, the thymus has shrunk by approximately 90%. As the thymus shrinks, so does its production of the signaling molecules that coordinate immune function, including Thymosin Alpha-1.

A 2025 review in the International Journal of Molecular Sciences found that Thymosin Alpha-1 may help improve vaccine response in elderly patients and support mitigation of immune decline associated with aging by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity.

Thymosin Alpha-1 does not directly attack pathogens the way an antibiotic does. It functions more like an orchestra conductor, helping coordinate the immune response rather than replacing any individual instrument. Research has explored its potential role in chronic viral infections including hepatitis B and C, influenza, COVID-19, cancer support, immune deficiencies, and healthy aging. A 2024 narrative review covering clinical studies across more than 11,000 human subjects found consistent evidence of Thymosin Alpha-1's safety across COVID-19, autoimmune conditions, and cancer settings.

It is worth noting that Thymosin Alpha-1 is approved in more than 35 countries under the brand name Zadaxin, primarily for hepatitis B, making it one of the few therapeutic peptides with established international clinical approval. Most of the clinical data in the United States remains in defined disease states rather than healthy aging populations, and large-scale randomized trials in otherwise healthy adults are still limited. That distinction matters when evaluating claims.

Thymosin Alpha-1 is not appropriate for everyone. Individuals who are intentionally suppressing their immune system, those with certain cancers, or those who have received organ transplants require careful evaluation before considering this therapy.

BPC-157: Tissue Repair From an Unlikely Source

BPC stands for Body Protection Compound. The 157 refers to the length of the original protein fragment from which it was derived. Its origin is not a laboratory. It comes from the stomach.

The stomach is exposed to one of the strongest acids in the body, yet it does not digest itself. Every few days it renews its lining, continuously repairing tiny injuries, regulating blood flow, and maintaining its protective barrier. Scientists studied what protects and repairs the stomach so efficiently, and that investigation led to the discovery of protective compounds within gastric juice, one of which became the basis for BPC-157.

Experimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue.

Angiogenesis, the formation of new blood vessels, is one of the first priorities after tissue injury. Without restored blood flow, healing cannot proceed efficiently. Fibroblasts are the specialized cells that lay down collagen and rebuild damaged structures. Research suggests BPC-157 may influence both of these processes during healing.

Because of its gastric origins, BPC-157 is also one of the few therapeutic peptides that can be taken orally to support the digestive tract specifically. Research has explored its effects on the stomach lining, intestinal barrier integrity, recovery from ulcers and inflammatory bowel disease, and healing following damage from anti-inflammatory medications. It has also received significant attention in sports medicine for tendon, ligament, and muscle recovery, areas where the research base continues to grow. In one human study, 7 out of 12 people with chronic knee pain felt relief for over six months after receiving a single BPC-157 knee injection.

It is important to be honest about where the evidence stands. The majority of BPC-157 research is preclinical, meaning it has been conducted in animal and laboratory models. Human clinical trials are still limited, and larger, well-designed trials are needed before definitive conclusions can be drawn. BPC-157 is not FDA-approved for any condition in the United States. At Valley Vital Medicine, we present it as a therapy with promising preclinical support and a favorable safety profile observed in research to date, not as an established medical treatment.

TB-500: Cell Migration and Tissue Remodeling

TB-500 is a synthetic fragment of a naturally occurring peptide called Thymosin Beta-4. Unlike Thymosin Alpha-1, which originates primarily in the thymus, Thymosin Beta-4 is found throughout the body in high concentrations, present in platelets, white blood cells, skin, cornea, heart tissue, and actively healing tissue of all kinds.

Where BPC-157 is often described as the repair crew, TB-500 functions more like the project manager. Its primary role involves a protein called actin, which forms part of the internal skeleton of cells and enables cells to move. When tissue is damaged, immune cells, fibroblasts, and blood vessel cells all need to migrate into the injured area. Nothing heals if those cells cannot get to where they are needed. Research suggests Thymosin Beta-4 influences these cell migration pathways and may also play a role in angiogenesis and in regulating the transition from acute inflammation toward tissue remodeling.

It is critical to be clear about the evidence base for TB-500 specifically. As of early 2026, no completed, published human randomized controlled trials have examined TB-500 for any musculoskeletal or tissue-repair indication. Most of the research has been conducted using Thymosin Beta-4, the full parent protein, in animal and laboratory models. The 2025 scoping review on TB-500 and Thymosin Beta-4 found the evidence base weighted toward preclinical designs, with human data still very limited. TB-500 is also currently listed by WADA as a prohibited substance in competitive sports.

That does not mean the underlying science is without merit. Research on Thymosin Beta-4 itself is encouraging and continues to expand. A 2025 study in Cardiovascular Research provided early human evidence in cardiac patients. But it does mean that anyone considering TB-500 should do so with realistic expectations, under clinical oversight, and with a clear understanding of where the evidence currently stands.

BPC-157 and TB-500 are frequently discussed together and sometimes used in combination because their proposed mechanisms complement each other. BPC-157 appears to support connective tissue repair and GI healing, while TB-500 appears to support cell migration and tissue remodeling. Whether combining them produces effects greater than either alone has not been established in human trials.

How Valley Vital Medicine Approaches Peptide Therapy

Our philosophy is to be open to emerging therapies and grounded in evidence and patient safety at the same time. We do not chase trends, and we do not dismiss new science simply because it is new. What we do is evaluate the research honestly, consider each patient's full medical history, and make individualized recommendations based on goals, risk factors, and current evidence.

When peptides are part of a patient's plan at Valley Vital Medicine, they come from licensed compounding pharmacies that meet rigorous quality and sterility standards. Clinical oversight, appropriate lab monitoring, and clear outcome tracking are part of how we use these tools responsibly.

Peptides are not a magic bullet. They work best as part of a broader strategy that includes nutrition, sleep, stress management, hormone optimization, and addressing root cause contributors to whatever health challenges a patient is navigating. What they can offer, in the right context and with the right sourcing, is targeted support for the body's own healing and communication systems.

If you are curious about whether peptide therapy might be appropriate for your specific health goals, we would love to have that conversation with you.

Call 701-532-1926 or visit www.valleyvitalmedicine.com to schedule your free discovery call and learn how peptide therapy and our root-cause approach can help you optimize your health.

Medical Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. Peptide therapies discussed in this article are not FDA-approved for the conditions mentioned unless otherwise noted. Always consult a qualified healthcare provider before beginning any new therapy.

References:

1. International Journal of Molecular Sciences. Thymosin Alpha-1 and immune aging: a multi-system review. November 2025.
2. Meto Research. Thymosin Alpha-1 safety review across 11,000+ subjects. 2024.
3. Expert Consensus on Clinical Application of Thymosin Alpha-1 in Infectious Diseases and Critical Care Medicine. Infect Microb Dis. 2025;7(2):76-83.
4. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495.
5. MDPI. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026.
6. MDPI Applied Sciences. Thymosin Beta-4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair: a scoping review. 2026.
7. Zhang et al. Recombinant human Thymosin Beta-4 in ischemic cardiac dysfunction. Cardiovascular Research. 2025.